According to the sources sought notice posted on SAM.gov Wednesday, the proposed contract has a potential value of $338.5 million and is intended to support the DTRA Operations Integration ...
AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on ...
2h
Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company targeting rare diseases, has selected IBN to manage its corporate communications an ...
Broader protection induced by combination of COVID adenovirus vaccine plus CiVax TM compared to 2-shot mRNA vaccination series ...
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...
Tonix Pharmaceuticals Holding Corp. announced that the FDA has set a PDUFA goal date of August 15, 2025, for TNX-102 SL, which, if approved, would be the first new drug for fibromyalgia in over 15 ...
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback